AXIOS (Caitlin Owens) - Longevity medicine's do-or-die moment
The world's first human trial of whether a drug can essentially make a person's cells younger sets up a reality check for one of the longevity field's most promising theories. Why it matters: The early-stage clinical trial will signal whether "cellular reprogramming" can be performed safely in humans, a prerequisite for any future claim that a treatment can slow or even reverse biological aging. The big picture: Attempts to prolong the human lifespan can refer to anything from better diet and exercise to the infusion of blood plasma from young donors. - The former is validated by decades of science; the latter has merited two warnings from the Food and Drug Administration that said such treatments lack any evidence of clinical benefit. …